Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA

作者:Risitano Antonio Maria*; Selleri Carmine; Serio Bianca; Torelli Giovanni Fernando; Kulagin Alexander; Maury Sebastien; Halter Joerg; Gupta Vikas; Bacigalupo Andrea; Socie Gerard; Tichelli Andre; Schrezenmeier Hubert; Marsh Judith; Passweg Jakob; Rotoli Bruno
来源:British Journal of Haematology, 2010, 148(5): 791-796.
DOI:10.1111/j.1365-2141.2009.08027.x

摘要

An alemtuzumab-based experimental immunosuppressive treatment (IST) regimen was investigated in 35 patients with severe aplastic anaemia (SAA), pure red cell (PRCA) or pure white cell aplasia (PWCA). Alemtuzumab total dose was 73-103 mg s.c., followed by cyclosporine. No serious toxicity due to the regimen was observed. Adverse events were clinically irrelevant; infectious events were rare. The total response rate was 58%, 84% and 100% in SAA, PRCA and PWCA, respectively, with corresponding 6 months cumulative response probabilities of 84%, 84% and 100%. Subcutaneous alemtuzumab is a feasible and sufficiently safe IST regimen for patients suffering from immune-mediated marrow failures.

  • 出版日期2010-3